Ginkgo Bioworks Holdings, Inc. ((DNA)) has held its Q1 earnings call. Read on for the main highlights of the call.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ginkgo Bioworks’ latest earnings call struck a tone of cautious optimism, with management highlighting rapid progress in autonomous labs, AI-driven experimentation, and new partnerships, even as the company grapples with a steep revenue drop and persistent losses. Executives framed 2026 as a crucial execution year in which scaling Nebula and commercializing new platforms must begin translating into durable, recurring revenue.
Fortress Balance Sheet: Strong Cash, No Debt
Ginkgo emphasized its solid financial footing, ending Q1 2026 with $373 million in cash and no bank debt, giving the company room to keep investing despite current losses. Management portrayed this cash runway as a strategic asset to fund Nebula, cloud lab expansion, and AI initiatives without near-term financing pressure.
Restructuring Cuts Deep into Costs
The company reported a sharp reset in operating expenses, with R&D down 38% year-over-year to $30 million and G&A down 35% to $13 million, reflecting restructuring actions. Net loss from continuing operations improved modestly to $76 million from $83 million, signaling progress but underscoring that the path to profitability remains long.
Cash Burn Trend Improves, Guidance Reaffirmed
Quarterly cash burn improved to $48 million in Q1 2026, a 17% reduction from $58 million a year earlier, confirming early benefits from cost cuts and portfolio changes. Management reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million, describing cash usage as the clearest metric of underlying business performance.
Nebula Autonomous Lab Scales Up Aggressively
Nebula, Ginkgo’s flagship autonomous lab platform, is scaling quickly from about 50 racks toward a planned 103 to 105 racks, signaling a major capacity ramp. The system now runs over 100 protocols, integrates more than 80 devices, and logged a peak day with roughly 439 scientists submitting protocols, a key indicator of user traction.
New Contracts and Strategic Spin-Off Unlock Capital
On the commercial front, Ginkgo signed a $47 million deal with Pacific Northwest National Labs for a large autonomous lab deployment, validating Nebula’s appeal to sophisticated customers. The company also completed the spin-off of its biosecurity unit, Perimeter, raising $60 million in new capital while retaining exposure as a shareholder.
AI-Designed Experiments Show Measurable Performance Gains
Ginkgo showcased a marquee AI collaboration, highlighting an OpenAI project where GPT-5 designed lab experiments that improved the cost of cell-free protein synthesis by 40% versus the scientific state-of-the-art after six design rounds. Management framed this result as tangible proof that AI-driven workflows can materially enhance experimental efficiency and outcomes.
Cloud Lab, DataPoints and Channels Build a Commercial Stack
The company launched its cloud lab portal, cloud.ginkgo.bio, offering posted protocols and transparent pricing to lower the barrier for customers to tap its automated capabilities. DataPoints, its data-focused offering, has already onboarded 10 top biopharma customers, while new sales channels via AWS, Benchling, and Tamarind Bio aim to funnel more demand into the platform.
Top-Line Hit: Revenue Almost Halved
Despite technical and commercial wins, financial results showed a sharp top-line contraction, with Q1 2026 revenue falling to $19 million, down 49% year-over-year. Even after stripping out $7.5 million of prior-year noncash BiomEdit termination revenue, the decline was still a steep 37%, underscoring execution risk on monetization.
Losses Persist and EBITDA Remains Deeply Negative
Adjusted EBITDA stayed firmly in the red at negative $42 million in Q1 2026, only slightly better than the prior year’s negative $44 million, as revenue weakness offset cost savings. The net loss from continuing operations of $76 million, while improved, still highlights that Ginkgo is far from breakeven and dependent on its cash reserves.
Excess Lease Space Weighs on Profitability
A significant drag on earnings remains Ginkgo’s excess leased lab space, which carried a $16 million cost in Q1 2026, net of sublease income. Management acknowledged this is a cash cost embedded in adjusted EBITDA and emphasized that improved subleasing or footprint optimization is necessary to ease the near-term profitability burden.
Google Cloud Reset Adds Short-Term Pain, Long-Term Relief
The quarter’s cash burn was inflated by a $14 million payment to Google Cloud tied to resetting a long-term commitment, which extended the agreement from three to six years. While this step pressured Q1 cash flow, it reduced future minimum commitments by more than $100 million, lowering structural cloud cost obligations over time.
Scaling Nebula Brings Real Technical Growing Pains
Management was candid that scaling Nebula is not frictionless, noting that “things break” as racks, devices, and protocols multiply. Complex scheduling, device integration challenges, and debugging issues are active pain points, and the team must keep pace operationally as capacity and customer use increase.
New Channels Still Need to Prove Revenue Power
Ginkgo stressed that its emerging channels—including cloud lab self-serve access and partnerships with AWS, Benchling, and Tamarind—are still in early innings. While strategically promising, management cautioned that these are nascent sales routes, and it remains uncertain how quickly they can translate into meaningful revenue streams.
Competitive and Global Cost Pressures Raise the Stakes
The call highlighted an increasingly competitive landscape, with new autonomous lab entrants and international players in lower-cost regions such as China pressuring R&D economics. Ginkgo argued that this environment increases urgency for U.S. lab efficiency and positions Nebula as a potential answer, but also heightens execution risk if it falls behind.
Guidance Signals Tight Cost Control Amid Revenue Pressure
Looking ahead, Ginkgo reaffirmed its 2026 cash burn guidance of $125 million to $150 million, leaning on its $373 million cash balance and zero debt to navigate a choppy revenue backdrop. With Q1 revenue at $19 million, reduced R&D and G&A, negative adjusted EBITDA of $42 million, and a one-off cloud payment behind it, the company framed future quarters as a test of whether its leaner cost base and new platforms can stabilize growth.
Ginkgo’s earnings call painted a story of a company at an inflection point, pairing bold bets on autonomous biology and AI with disciplined cost cuts and a fortified balance sheet. For investors, the upside hinges on whether Nebula, the cloud lab, and channel partnerships can convert technical momentum into sustainable revenue before the sizable cash cushion erodes.